Elevated PRK1 levels and phosphorylated H3T11 correlate with prostate cancer aggressiveness, suggesting PRK1 inhibition as a potential therapeutic strategy for blocking AR-induced tumor proliferation (78). The gene discussed is AR; the disease is prostate carcinoma.